Letermovir Prophylaxis Cuts Risk of CMV Infection

This article originally appeared here.
Share this content:
Letermovir Prophylaxis Cuts Risk of CMV Infection
Letermovir Prophylaxis Cuts Risk of CMV Infection

THURSDAY, Dec. 7, 2017 (HealthDay News) -- For cytomegalovirus (CMV)-seronegative patients undergoing hematopoietic-cell transplantation, letermovir prophylaxis is associated with a lower risk of CMV infection than placebo, according to a study published online Dec. 6 in the New England Journal of Medicine.

Francisco M. Marty, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues randomized CMV-seropositive transplant recipients in a 2:1 ratio to receive letermovir or placebo through week 14 after transplantation. The trial regimen was discontinued in patients in whom clinically significant CMV infection developed, and they received anti-CMV treatment.

The researchers found that among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group had clinically significant CMV infection or were classified as having a primary end point event by week 24 after transplantation, compared with the placebo group (37.5 versus 60.6 percent; P < 0.001). The two groups had similar frequency and severity of adverse events. Vomiting occurred in 18.5 and 13.5 percent of those who received letermovir and placebo, respectively; edema in 14.5 and 9.4 percent, respectively; and atrial fibrillation or flutter in 4.6 and 1.0 percent, respectively. Similar rates of myelotoxic and nephrotoxic events were seen in both groups.

"Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo," the authors write. "Adverse events with letermovir were mainly of low grade."

The study was funded by Merck, the manufacturer of letermovir.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Bayer Stops U.S. Sale of Essure Birth Control Implant

Bayer Stops U.S. Sale of Essure Birth Control ...

Problems with device include chronic pain and perforations of the uterus and fallopian tubes

C.S. Mott Poll Addresses Child Safety at Amusement Parks

C.S. Mott Poll Addresses Child Safety at Amusement ...

2016 saw U.S. emergency departments deal with 30,000 injuries linked to amusement parks, carnivals

Greening Vacant Land Improves Neighborhood Mental Health

Greening Vacant Land Improves Neighborhood Mental Health

Cleaning up vacant lots in resource-limited urban settings can aid residents' mental health

is free, fast, and customized just for you!




Already a member?

Sign In Now »